Anti-PTRH2 monoclonal antibody

Pre-made anti-PTRH2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to PTRH2/PTRH2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1461-Ab-1/ GM-Tg-hg-IP1461-Ab-2Anti-Human PTRH2 monoclonal antibodyHuman
GM-Tg-rg-IP1461-Ab-1/ GM-Tg-rg-IP1461-Ab-2Anti-Rat PTRH2 monoclonal antibodyRat
GM-Tg-mg-IP1461-Ab-1/ GM-Tg-mg-IP1461-Ab-2Anti-Mouse PTRH2 monoclonal antibodyMouse
GM-Tg-cynog-IP1461-Ab-1/ GM-Tg-cynog-IP1461-Ab-2Anti-Cynomolgus/ Rhesus macaque PTRH2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1461-Ab-1/ GM-Tg-felg-IP1461-Ab-2Anti-Feline PTRH2 monoclonal antibodyFeline
GM-Tg-cang-IP1461-Ab-1/ GM-Tg-cang-IP1461-Ab-2Anti-Canine PTRH2 monoclonal antibodyCanine
GM-Tg-bovg-IP1461-Ab-1/ GM-Tg-bovg-IP1461-Ab-2Anti-Bovine PTRH2 monoclonal antibodyBovine
GM-Tg-equg-IP1461-Ab-1/ GM-Tg-equg-IP1461-Ab-2Anti-Equine PTRH2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1461-Ab-1/ GM-Tg-hg-IP1461-Ab-2; GM-Tg-rg-IP1461-Ab-1/ GM-Tg-rg-IP1461-Ab-2;
GM-Tg-mg-IP1461-Ab-1/ GM-Tg-mg-IP1461-Ab-2; GM-Tg-cynog-IP1461-Ab-1/ GM-Tg-cynog-IP1461-Ab-2;
GM-Tg-felg-IP1461-Ab-1/ GM-Tg-felg-IP1461-Ab-2; GM-Tg-cang-IP1461-Ab-1/ GM-Tg-cang-IP1461-Ab-2;
GM-Tg-bovg-IP1461-Ab-1/ GM-Tg-bovg-IP1461-Ab-2; GM-Tg-equg-IP1461-Ab-1/ GM-Tg-equg-IP1461-Ab-2
Products NameAnti-PTRH2 monoclonal antibody
Formatmab
Target NamePTRH2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-PTRH2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1461-Ag-1Recombinant multi-species PTH2/ PTRH2/ BIT1 protein


    Target information

    Target IDGM-IP1461
    Target NamePTRH2
    Gene ID51651,217057,287593,711736,100682594,101093219,516595,100071096
    Gene Symbol and SynonymsA230072I16Rik,BIT1,CFAP37,CGI-147,IMNEPD,PTH,PTH 2,PTH2,PTRH2,RGD1306819
    Uniprot AccessionQ9Y3E5,Q3ZBL5
    Uniprot Entry NamePTH2_HUMAN,PTH2_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000141378
    Target ClassificationN/A

    The target: PTRH2, gene name: PTRH2, also named as BIT1, CFAP37, CGI-147, IMNEPD, PTH, PTH 2, PTH2. The protein encoded by this gene is a mitochondrial protein with two putative domains, an N-terminal mitochondrial localization sequence, and a UPF0099 domain. In vitro assays suggest that this protein possesses peptidyl-tRNA hydrolase activity, to release the peptidyl moiety from tRNA, thereby preventing the accumulation of dissociated peptidyl-tRNA that could reduce the efficiency of translation. This protein also plays a role regulating cell survival and death. It promotes survival as part of an integrin-signaling pathway for cells attached to the extracellular matrix (ECM), but also promotes apoptosis in cells that have lost their attachment to the ECM, a process called anoikos. After loss of cell attachment to the ECM, this protein is phosphorylated, is released from the mitochondria into the cytosol, and promotes caspase-independent apoptosis through interactions with transcriptional regulators. This gene has been implicated in the development and progression of tumors, and mutations in this gene have been associated with an infantile multisystem neurologic, endocrine, and pancreatic disease (INMEPD) characterized by intellectual disability, postnatal microcephaly, progressive cerebellar atrophy, hearing impairment, polyneuropathy, failure to thrive, and organ fibrosis with exocrine pancreas insufficiency (PMID: 25574476). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.